Benzinga | Jul 30, 2021 10:53AM EDT

Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $323

Piper Sandler analyst Edward Tenthoff maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $261 to $323.